Researchers are conducting a phase 3 study to compare inavolisib plus fulvestrant with alpelisib plus fulvestrant in patients with HR+, HER2-, PIK3CA-mutated advanced breast cancer.
Researchers are conducting a phase 1 study to evaluate AND019 in postmenopausal patients with advanced or metastatic ER+/HER2- breast cancer.
Researchers are conducting a phase 3 trial to compare sotorasib plus panitumumab with investigator’s choice of therapy in patients with previously treated, KRAS p.G12C-mutated metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare standard care with combination tucatinib, trastuzumab, and chemotherapy as first-line treatment in HER2-positive, unresectable or metastatic colorectal cancer.
Researchers are comparing nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice of chemotherapy in MSI-H/dMMR, recurrent or metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare XL092 plus atezolizumab with regorafenib alone in MSS/MSI-low metastatic colorectal cancer.
Researchers are conducting a phase 2 trial to test pembrolizumab and tamoxifen, with or without vorinostat, in patients with ER+ breast cancer.
Researchers are testing valemetostat plus trastuzumab deruxtecan in patients with HER2-low/ultra-low/null metastatic breast cancer.
Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced, PIK3CA-mutant, HER2+ breast cancer.
Researchers are conducting a phase 1 trial to test CAR T-cell therapy in patients with mesothelin-expressing triple-negative breast cancer.
